Garcia et al. utilized a medium-throughput drug-screening system to identify a library of protein kinase inhibitor drugs already in various stages of clinical trials that are capable of targeting SARS-CoV-2 activity in the body. After a primary screening of 430 drugs demonstrating that 34 of the kinase inhibitors blocked SARS-CoV-2 infection in an infectious cell culture system using Vero E6 cells, a drug-cellular protein interaction network was determined by mining the compounds against the STITCH database. It was found that specific proteins in a limited set of signaling pathways are crucial to SARS-CoV-2 infection and thus should be targeted by antiviral agents. A secondary screening showed that berzosertib, an ATR kinase inhibitor, demonstrated the most potent anti-SARS-CoV-2 activity among a variety of cell types. After a study of mechanism of action, it was found that berzosertib operated in a good therapeutic window and inhibited viral replication at a post-entry step. From these results, the researchers assert that berzosertib can be a treatment option for individuals with ongoing SARS-CoV-2 infections once further research focuses on a determination of a combination of drug candidates for use alongside berzosertib, which is not a standalone therapy.